commercial has steady financial progress XXXX, made in Thank you, while Iovance XXXX the Igor. our launch discipline. Throughout and preparations, team maintaining into
our engagement launch Our and payer include activities. the readiness onboarding of related operational centers authorized treatment or priorities ATCs,
cross-functional build centers line Our their TIL U.S. continue cancer leading to to service teams partner capability. with
Our is training approval. designed to program FDA regimen ensure can teams lifileucel cross-disciplinary treatment the upon administer
CAR-T Our goal centers top market account XX about the This CAR-T account is launch. XX XX% that to for onboard ATCs CAR-T centers of indicate the patients. the about XX% the by per our claims top for XX and is at assessment data least the of informed where patients, treated treated number of
a the commercialization potential lifileucel. our for across We ATCs of similar concentration expect
ATC and lifileucel goal the sites and is TIL training BLA-related milestones timing U.S. longer-term have just-in-time aligned The of planned be few drive onboarding most therapy. offering Our to within ensure that to so our key and is to enough ATCs. patients hours readiness can execution to an training at in a
BLA of payers team potential Although, the for team clinical critical patients appreciate is launch, built XX% XX% engaged there core In and melanoma significant for and launch. the amount commercial these Medicare to has the our responsible is more rapidly the unmet of the for commercial between of scale and approximately foundation than a submission of at lives. access work market with as last Medicaid access believe a also year, and patient occur Reimbursement will the need responsible covered factor for on our value our that interactions, states as covered that payers lifileucel well metastatic Based lives we cancer. efficiently.
is Medicare In secure designed are approval, will coverage to strategies other XXXX, payment important an because and CAR-T hospitals include payment. lifileucel. achievement appropriate coding, reimbursement This upon expanded have including and beneficiaries. more milestone Medicare XX to Our DRG for lifileucel immunotherapies,
BLA and as prepare for payers continue plan we and We commercialization. submission to for engage CMS
We of our remains are Cares progress on track also pleased launch. program, with Iovance which for the
that best-in-class goal patient to the Cares system. of the of at physicians ordering cell identity includes ATCs proprietary of Our and custody system every deliver chain is step Iovance patients, chain assist process. and and a our support
approach Officer, and our to to integrated our Our our progress. quality. highlight call Finckenstein, now clinical will approach Chief patient to Friedrich Medical pass management the I